These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 22726802)

  • 1. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial.
    Sandberg T; Skoog G; Hermansson AB; Kahlmeter G; Kuylenstierna N; Lannergård A; Otto G; Settergren B; Ekman GS
    Lancet; 2012 Aug; 380(9840):484-90. PubMed ID: 22726802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.
    van Nieuwkoop C; van der Starre WE; Stalenhoef JE; van Aartrijk AM; van der Reijden TJ; Vollaard AM; Delfos NM; van 't Wout JW; Blom JW; Spelt IC; Leyten EM; Koster T; Ablij HC; van der Beek MT; Knol MJ; van Dissel JT
    BMC Med; 2017 Apr; 15(1):70. PubMed ID: 28366170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial.
    Kazemier BM; Koningstein FN; Schneeberger C; Ott A; Bossuyt PM; de Miranda E; Vogelvang TE; Verhoeven CJ; Langenveld J; Woiski M; Oudijk MA; van der Ven JE; Vlegels MT; Kuiper PN; Feiertag N; Pajkrt E; de Groot CJ; Mol BW; Geerlings SE
    Lancet Infect Dis; 2015 Nov; 15(11):1324-33. PubMed ID: 26255208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.
    Talan DA; Stamm WE; Hooton TM; Moran GJ; Burke T; Iravani A; Reuning-Scherer J; Church DA
    JAMA; 2000 Mar 22-29; 283(12):1583-90. PubMed ID: 10735395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
    Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
    Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
    Talan DA; Klimberg IW; Nicolle LE; Song J; Kowalsky SF; Church DA
    J Urol; 2004 Feb; 171(2 Pt 1):734-9. PubMed ID: 14713799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.
    Bach D; van den Berg-Segers A; Hübner A; van Breukelen G; Cesana M; Plétan Y
    J Urol; 1995 Jul; 154(1):19-24. PubMed ID: 7776420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial.
    Vogel T; Verreault R; Gourdeau M; Morin M; Grenier-Gosselin L; Rochette L
    CMAJ; 2004 Feb; 170(4):469-73. PubMed ID: 14970093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
    Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
    Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.
    Mombelli G; Pezzoli R; Pinoja-Lutz G; Monotti R; Marone C; Franciolli M
    Arch Intern Med; 1999 Jan; 159(1):53-8. PubMed ID: 9892331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.
    Bernard L; Dinh A; Ghout I; Simo D; Zeller V; Issartel B; Le Moing V; Belmatoug N; Lesprit P; Bru JP; Therby A; Bouhour D; Dénes E; Debard A; Chirouze C; Fèvre K; Dupon M; Aegerter P; Mulleman D;
    Lancet; 2015 Mar; 385(9971):875-82. PubMed ID: 25468170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
    Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
    BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.